Atossa Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Atossa Therapeutics, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial positions and stock-related information.</b>

AI Summary

ATOSSA THERAPEUTICS, INC. (ATOS) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Atossa Therapeutics, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and comparative periods. Key financial statement items such as common stock, retained earnings, and additional paid-in capital are detailed. Information regarding stock incentive plans, warrants, and preferred stock is also presented. The company's business address is 107 Spring Street, Seattle, WA 98104, with a phone number of 206.588.0256.

Why It Matters

For investors and stakeholders tracking ATOSSA THERAPEUTICS, INC., this filing contains several important signals. This filing provides investors with the latest financial performance and balance sheet details for Atossa Therapeutics, enabling informed investment decisions. The report's comprehensive data on equity, liabilities, and stock instruments is crucial for understanding the company's financial health and potential future capital structure.

Risk Assessment

Risk Level: medium — ATOSSA THERAPEUTICS, INC. shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, clinical trial risks, and market competition, as indicated by its SIC code [2834].

Analyst Insight

Review the detailed financial statements and risk factors in the 10-Q to assess Atossa Therapeutics' current financial health and future prospects.

Key Numbers

• 2024-03-31 — Period End Date (Conformed Period of Report)
• 2024-05-13 — Filing Date (Filed as of Date)
• 2024-01-01 — Q1 2024 Start Date (Reporting period for Q1 2024)
• 2023-03-31 — Q1 2023 End Date (Comparative period)

Key Players & Entities

• ATOSSA THERAPEUTICS, INC. (company) — Filer name
• ATOS (company) — Ticker symbol
• 2024-03-31 (date) — Period of report
• 2024-05-13 (date) — Filing date
• 2834 (industry_code) — Standard Industrial Classification
• 107 SPRING STREET (address) — Business address
• SEATTLE (location) — Business address city
• WA (location) — Business address state

FAQ

Risk Factors

• Regulatory Risks [medium — regulatory]: The company is subject to extensive regulation by government authorities, which can impact product development, approval, and marketing.
• Market Competition [medium — market]: The pharmaceutical market is highly competitive, with potential for new entrants and existing competitors to impact market share and pricing.
• Clinical Trial Risks [high — operational]: The success of drug development is contingent on successful clinical trials, which are inherently uncertain and can face delays or failure.

Key Dates

• 2024-03-31: Quarterly Period End — The end date for the financial reporting period covered by this 10-Q filing.
• 2024-05-13: Filing Date — The date this 10-Q report was officially filed with the SEC.

Key Financial Figures

• $0.18 — nge on which registered Common Stock, $0.18 par value ATOS The Nasdaq Capital M

Filing Documents

• atos-20240331.htm (10-Q) — 1161KB
• atos-ex31_1.htm (EX-31.1) — 13KB
• atos-ex31_2.htm (EX-31.2) — 13KB
• atos-ex32_1.htm (EX-32.1) — 8KB
• atos-ex32_2.htm (EX-32.2) — 8KB
• img96389207_0.jpg (GRAPHIC) — 105KB
• 0000950170-24-058244.txt (&nbsp;) — 5330KB
• atos-20240331.xsd (EX-101.SCH) — 992KB
• atos-20240331_htm.xml (XML) — 605KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22 PART II. OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43 Item 3. Defaults Upon Senior Securities 43 Item 4. Mine Safety Disclosures 43 Item 5. Other Information 43 Item 6. Exhibits 44

—FINA NCIAL INFORMATION

PART I—FINA NCIAL INFORMATION

CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS - UNAUDITED

ITEM 1. CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS - UNAUDITED ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED B ALANCE SHEETS (amounts in thousands, except share and per share data) (Unaudited) March 31, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 83,960 $ 88,460 Restricted cash 110 110 Prepaid materials 1,372 1,487 Prepaid expenses and other current assets 1,613 2,162 Total current assets 87,055 92,219 Investment in equity securities 1,710 1,710 Other assets 2,322 2,323 Total assets $ 91,087 $ 96,252 Liabilities and stockholders' equity Current liabilities Accounts payable $ 1,230 $ 806 Accrued expenses 1,613 973 Payroll liabilities 659 1,654 Other current liabilities 1,826 1,803 Total current liabilities 5,328 5,236 Total liabilities 5,328 5,236 Commitments and contingencies (Note 13) Stockholders' equity Convertible preferred stock - $ 0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of March 31, 2024 and December 31, 2023 — — Common stock - $ 0.18 par value; 175,000,000 shares authorized; 125,507,814 and 125,304,064 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 22,829 22,792 Additional paid-in capital 256,571 255,987 Treasury stock, at cost; 1,320,046 shares of common stock at March 31, 2024 and December 31, 2023 ( 1,475 ) ( 1,475 ) Accumulated deficit ( 192,166 ) ( 186,288 ) Total stockholders' equity 85,759 91,016 Total liabilities and stockholders' equity $ 91,087 $ 96,252 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 3 ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STAT EMENTS OF OPERATIONS (amounts in thousands, except share and per share data) (Unaudited) For the Three Months Ended March 31, 2024 2023 Oper

View Full Filing

View this 10-Q filing on SEC EDGAR